Drug Development

David Vodak, PhD, is senior director at Capsugel’s Bend, Oregon facility.

is head of Solid Form Services at Lonza Pharma & Biotech and was previously 

principal scientist at Capsugel’s Bend, Oregon facility.

Articles

Model-based formulation and technology selection methodologies facilitate rapid product development.


Selecting the Appropriate Technology for Oral Bioavailability Enhancement

The pharmaceutical packaging and drug delivery conference has announced its event program taking place on Feb. 7–8, 2018 at Paris Expo Porte de Versailles in France.

Pharmapack Europe 2018 Announces Event Program

The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.

FDA Approves GSK’s Shingles Vaccine

AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.

AbbVie and Alector Partner on Alzheimer’s Disease Immunotherapies

The new BioLive event, which will be a global hub for biopharmaceutical manufacturing, will launch alongside CPhI Worldwide 2018 in Madrid.


UBM Announces BioLive Event

Inovio has reported results from a study with non-human primates that showed 100% effectiveness with a DNA vaccine the company is developing with the US Army.

Inovio Reports on DNA Vaccine It is Developing with US Army

ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility. 

ABEC Develops Single-Use Bioreactor for Emergent Manufacturing Facility

The agency has published educational material for physicians promoting the benefits of biosimilars.

FDA Promotes Biosimilars Use

The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.

Ventria Bioscience Receives $4.2-Million Grant for Intestinal Infection Treatments

The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.

Formulation and Drug Delivery